Takeuchi, Masashi
Kawakubo, Hirofumi
Saito, Kosuke
Maeda, Yusuke
Matsuda, Satoru
Fukuda, Kazumasa
Nakamura, Rieko
Kitagawa, Yuko
Article History
Received: 10 February 2022
Accepted: 11 May 2022
First Online: 28 June 2022
Disclosures
: Yuko Kitagawa received lecture fees from Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd, Asahi Kasei Pharma Corporation, Otsuka Pharmaceutical Factory, Inc., Shionogi & Co., Ltd., Nippon Covidien, Inc., Ono Pharmaceutical Co., Ltd., and Bristol-Myers Squibb K.K. Yuko Kitagawa was supported by grants from Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd, Yakult Honsha Co. Ltd., Asahi Kasei Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Tsumura & Co., Kyouwa Hakkou Kirin Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., EA Pharma Co., Ltd., Astellas Pharma, Inc., Toyama Chemical Co., Ltd., Medicon, Inc., Kaken Pharmaceutical Co. Ltd., Eisai Co., Ltd., Otsuka Pharmaceutical Factory, Inc., Teijin Pharma Limited, Nihon Pharmaceutical Co., Ltd., and Nippon Covidien, Inc. Yuko Kitagawa held an endowed chair provided by Chugai Pharmaceutical Co., Ltd. and Taiho Pharmaceutical Co., Ltd, outside the submitted work.